Ulcerative colitis: Exceptional consequence after rituximab therapy.;La colite ulcérative: une conséquence exceptionnelle après traitement par rituximab

Annales Pharmaceutiques Francaises

Volumn 69, Issue 5, 2011, Pages 265-269

  Sekkach, Y ^a   Hammi, S ^a   Elqatni, M ^a   Fatihi, J ^a   Badaoui, M ^a   Elomri, N ^a   Mekouar, F ^a   Smaali, J ^a   Jira, M ^a   Amezyane, T ^a   Abouzahir, A ^a   Ghafir, D ^a  

^a MILITARY HOSPITAL MOHAMMED V   (Morocco)

Author keywords

Appendicitis; Lymphocyte depletion; Rituximab; Systemic erythematous lupus; Ulcerative colitis

Indexed keywords

CORTICOSTEROID; CYCLOPHOSPHAMIDE; HYDROXYCHLOROQUINE; METHOTREXATE; RITUXIMAB;

ABDOMINAL PAIN; ACUTE APPENDICITIS; ADULT; APPENDECTOMY; ARTICLE; CASE REPORT; CD8+ T LYMPHOCYTE; CELL INFILTRATION; DRUG RESISTANCE; DRUG WITHDRAWAL; FOLLOW UP; GENERAL ASPECTS OF DISEASE; HISTOPATHOLOGY; HUMAN; INFUSION; PATIENT MONITORING; SYSTEMIC LUPUS ERYTHEMATOSUS; ULCERATIVE COLITIS; VERNER MORRISON SYNDROME;

ABDOMINAL PAIN; ADULT; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; CD8-POSITIVE T-LYMPHOCYTES; COLITIS, ULCERATIVE; COLON; DIARRHEA; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOLOGIC FACTORS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE;

EID: 80052905956     PISSN: 00034509     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pharma.2011.06.005     Document Type: Article

References (11)

1. Leandro M.J., Edwards J.C., Cambridge G., Ehrenstein M.R., Isenberg D.A. An open study of B lymphocyte depletion in systemic lupus erythematosus. Arthritis Rheum 2002, 46:2673-2677.
2. Hatjiharissi E., Xu L., Santos D.D., Hunter Z.R., Ciccarelli B.T., Verselis S., et al. Increased natural killer cell expression of CD16, augmented binding and ADCC activity to rituximab among individuals expressing the Fc{gamma}RIIIa-158V/V and V/F polymorphism. Blood 2007, 110:2561-2564.
3. Eisenberg R., Looney R.J. The therapeutic potential of anti-CD20 " what do B-cells do?" Clin Immunol 2005, 117:207-213.
4. Sfikakis P.P., Boletis J.N., Lionaki S., Vigklis V., Fragiadaki K.G., Iniotaki A., et al. Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by downregulation of the T cell costimulatory molecule CD40 ligand: an open-label trial. Arthritis Rheum 2005, 52:501-513.
5. Anolik J.H., Barnard J., Owen T., Zheng B., Kemshetti S., Looney R.J., et al. Delayed memory B cell recovery in peripheral blood and lymphoid tissue in systemic lupus erythematosus after B cell depletion therapy. Arthritis Rheum 2007, 56:3044-3056.
6. Ng K.P., Cambridge G., Leandro M.J., Edwards J.C., Ehrenstein M., Isenberg D.A. B cell depletion therapy in systemic lupus erythematosus: long-term follow-up and predictors of response. Annals Rheum Dis 2007, 66:1259-1262.
7. Paran D., Trej'o L., Caspi D. Clinical images: B cell depletion in the appendix following rituximab treatment. Arthritis Rheum 2006, 54:2151.
8. Schroder C., Azimzadeh A.M., Wu G., Price J.O., Atkinson J.B., Pierson R.N. Anti-CD20 treatment depletes B-cells in blood and lymphatic tissue of cynomolgus monkeys. Transpl Immunol 2003, 12:19-28.
9. El Fassi D., Nielsen C.H., Kjeldsen J., Clemmensen O., Hegedüs L. Ulcerative colitis following B lymphocyte depletion with rituximab in a patient with Graves' disease. Gut 2008, 57:714-715.
10. Merrill JT, Neuwelt CM, Wallace DJ, Shanahan JC, Latinis KM, Oates JC, et al. Efficacy and safety of rituximab in patients with moderately to severely active systemic lupus erythematosus (SLE): results from the randomized, double-blind phase II/III study EXPLORER. ACR meeting 2008: abstract L12.
11. Jonsdottir T., Gunnarsson I., Risselada A., Henriksson E.W., Klareskog L., van Vollenhoven R.F. Treatment of refractory SLE with rituximab plus cyclophosphamide: clinical effects, serological changes, and predictors of response. Annals Rheum Dis 2008, 67:330-334.